美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

减肥药

1,225.62

-6.7316-0.55%

涨家数：2

跌家数：5

平家数：- -

市盈率：- -

高：1,236.18

开：1,232.97

低：1,221.74

收：1,232.35

数据加载中...

深耕的智慧：喧嚣时代的生物医药“长期主义”

建国路128号

辉瑞7月21日成交额为8.21亿美元

诺和诺德7月21日成交额为5.36亿美元

礼来7月21日成交额为23.39亿美元

最新13F文件披露11家机构近3个月对辉瑞股票调仓情况增减持各5家

安进7月21日成交额为5.98亿美元

硕迪生物盘中异动临近收盘急速跳水5.09%

太平洋医药日报：诺和诺德司美格鲁肽在华获批新适应症用于治疗慢性肾脏病

太平洋证券股份...

美国OTC市场Novo Nordisk A/S盘中异动快速下挫3.06%报62.60美元

方舟健客与诺和诺德签署合作备忘录，共筑健康管理新生态

诺和泰新增适应症；康华生物控股股东变更｜健讯Daily

21世纪经济报道

RootData：ALT 将于一周后解锁价值约 867 万美元的代币

安进7月18日成交额为5.83亿美元

美国OTC市场Novo Nordisk A/S盘中异动快速下跌3.12%报63.40美元

安进涨0.54% 股价突破300美元大关

【官宣！全球生物制药巨头诺和诺德牵手互联网慢病管理巨头方舟健客(06086.HK) 以AI重构控糖减重管理价值链共筑全

打造全周期智控慢病数智化标杆！方舟健客(06086)与诺和诺德签署合作备忘录，共筑健康管理新生态

诺和诺德寸步不让

生物制品圈

小细胞肺癌治疗重大突破！百济神州&安进双抗新药在华申报上市

刚刚！诺和诺德“司美格鲁肽注射液”新适应症国内获批上市

Insight数据库

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK4599/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4599","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"减肥药","latestPrice":1225.6226,"timestamp":1753127999999,"preClose":1232.3541,"halted":0,"volume":54728867,"delay":0,"changeRate":-0.005462,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":-6.731567,"latestTime":"07-21 16:00:00 EDT","open":1232.967,"high":1236.1781,"low":1221.7361,"amount":4442998518.990833,"amplitude":0.011719,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753191000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":9.433563,"peRate":31.277048,"turnoverRate":0.005173,"increases":2,"decrements":5,"flats":0,"marketCap":1312505341696,"floatMarketCap":1228030831456},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1236.1781,"amplitude":0.011719,"preClose":1232.3541,"low":1221.7361,"pbRate":"9.433563","latestPrice":1225.6226,"volume":54728867,"delay":0,"open":1232.967,"prevYearClose":1305.0607,"prevWeekClose":1232.3541,"prevMonthClose":1245.5326,"prevQuarterClose":1245.5326,"fiveDayClose":1279.8671,"twentyDayClose":1250.9895,"sixtyDayClose":1255.0566,"secType":"PLATE","market":"US","turnoverRate":0.005173,"peRate":31.277048,"marketCap":1312505341696,"floatMarketCap":1228030831456,"timestamp":1753127999999,"nameCN":"减肥药"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4599\",,,,undefined,":{"bkCode":"BK4599","up":2,"down":5,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2553238335","title":"深耕的智慧：喧嚣时代的生物医药“长期主义”","url":"https://stock-news.laohu8.com/highlight/detail?id=2553238335","media":"建国路128号","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553238335?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 15:11","pubTimestamp":1753168265,"startTime":"0","endTime":"0","summary":"而之所以在二级市场仍旧出圈，这背后折射出的，大概是其在喧嚣与浮躁中坚守“长期主义”的内在价值开始被市场重新发现和定价。放眼全球，丹麦的诺和诺德便是“长期主义”最完美的诠释者。图|诺和诺德股价走势图将目光转回国内，一批优秀的本土创新药企同样通过“长期主义”的践行，迎来了属于自己的高光时刻。最后，一家优秀的“长期主义”公司，其成功绝非依赖单一产品，而是一个整体性、连续性的系统。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722151356a6ba16f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722151356a6ba16f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","AAPG","DDC","BK4599","688235","LU0154236417.USD","LU1093756325.SGD","BK4532","688176","BK4585","IE00BZ1G4Q59.USD","NVO","ONC","LU1093756168.USD","06855","BK4007","BK4212","06160","IE00BKVL7J92.USD"],"gpt_icon":1},{"id":"2553818392","title":"辉瑞7月21日成交额为8.21亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553818392","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553818392?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 12:50","pubTimestamp":1753159803,"startTime":"0","endTime":"0","summary":"美东时间2025年7月21日，辉瑞成交额为8.21亿美元，成交额较昨日减少7.78%，当日成交量为3366.34万股。辉瑞于2025年7月21日跌0.86%，报24.26美元，该股过去5个交易日跌4.3%，年初至今跌5.27%，过去60日涨10.42%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-07-21|8.21亿|-7.78%|3366.34万|#|2025-07-18|8.90亿|-23.61%|3630.94万|#|2025-07-17|11.65亿|6.72%|4739.39万|#|2025-07-16|10.92亿|-19.27%|4421.82万|#|2025-07-15|13.53亿|105.01%|5445.80万|辉瑞是世界上最大的制药公司之一，年销售额约为600亿美元。辉瑞在全球销售这些产品，国际销售额占总销售额的40%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722125013a45b4b98&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722125013a45b4b98&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1894683264.USD","BK4585","LU0058720904.USD","SG9999001176.USD","IE0002270589.USD","LU0321505439.SGD","BK4588","SG9999011175.SGD","LU0225771236.USD","LU0456855351.SGD","BK4007","LU0306806265.USD","LU1066051498.USD","LU1894683348.USD","PFE","BK4581","LU1023059063.AUD","BK4599","SG9999002232.USD","LU0985481810.HKD","IE00B19Z3B42.SGD","IE00BBT3K403.USD","LU0225284248.USD","LU0321505868.SGD","LU0234572021.USD","SG9999013999.USD","IE00BLSP4239.USD","SGXZ57979304.SGD","LU1883839398.USD","SG9999003800.SGD","LU0170899867.USD","LU0289739699.SGD","SG9999002224.SGD","IE00B19Z3581.USD","IE00BLSP4452.SGD","BK4533","LU0306807586.USD","BK4592","LU1057294990.SGD","IE000M9KFDE8.USD","BK4568","BK4550","LU0122379950.USD","LU1066053197.SGD","LU0868494617.USD","BK4534","SG9999001176.SGD"],"gpt_icon":0},{"id":"2553289268","title":"诺和诺德7月21日成交额为5.36亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553289268","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553289268?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 12:28","pubTimestamp":1753158497,"startTime":"0","endTime":"0","summary":"美东时间2025年7月21日，诺和诺德成交额为5.36亿美元，成交额较昨日增加3.05%，当日成交量为828.07万股。诺和诺德于2025年7月21日涨0.95%，报64.92美元，该股过去5个交易日跌5.83%，年初至今跌23.51%，过去60日涨5.91%。诺和诺德还有一个生物制药部门，专门从事血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722122824a6b9c494&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722122824a6b9c494&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756325.SGD","IE00BKVL7J92.USD","BK4585","IE00BZ1G4Q59.USD","LU1093756168.USD","NVO","BK4007","BK4599","LU0154236417.USD","BK4588","BK4532"],"gpt_icon":1},{"id":"2553316286","title":"礼来7月21日成交额为23.39亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553316286","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553316286?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 11:22","pubTimestamp":1753154529,"startTime":"0","endTime":"0","summary":"美东时间2025年7月21日，礼来成交额为23.39亿美元，成交额较昨日减少9.59%，当日成交量为305.80万股。礼来于2025年7月21日跌1.23%，报762.18美元，该股过去5个交易日跌4.65%，年初至今跌0.91%，过去60日跌7.92%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-07-21|23.39亿|-9.59%|305.80万|#|2025-07-18|25.87亿|-18.22%|335.77万|#|2025-07-17|31.63亿|23.20%|410.73万|#|2025-07-16|25.68亿|-21.07%|325.54万|#|2025-07-15|32.53亿|69.96%|417.41万|礼来制药公司是一家专注于神经科学、心脏代谢、癌症和免疫学的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722112211a45b1b9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722112211a45b1b9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4534","LU1712237335.SGD","LU1989771016.USD","LU0122379950.USD","LU0234572021.USD","LU1093756325.SGD","LU1983299246.USD","SG9999001176.USD","LU0266013472.USD","BK4533","LU2063271972.USD","LU1127390331.HKD","SG9999014906.USD","LU0238689110.USD","LU1623119135.USD","LU0079474960.USD","LU1720051108.HKD","LU1814569148.SGD","LU2360106947.USD","SG9999001176.SGD","LU1868836757.USD","BK4599","LU2361044865.SGD","LU1868837136.USD","LU2471134796.USD","LU1551013425.SGD","LLY","LU0323591593.USD","LU1069344957.HKD","LU2461242641.AUD","LU1366192091.USD","LU2746668461.USD","SGXZ31699556.SGD","LU0109391861.USD","LU1280957306.USD","LU0889565916.HKD","LU2456880835.USD","LU0820561818.USD","IE00B1BXHZ80.USD","LU0203202063.USD","IE00BJT1NW94.SGD","LU2552382132.HKD","LU0106261372.USD","LU0385154629.USD","LU2265009873.SGD","IE00BJLML261.HKD","LU0640476718.USD","LU0114720955.EUR","LU2112291526.USD","IE00B2B36J28.USD"],"gpt_icon":1},{"id":"2553285592","title":"最新13F文件披露11家机构近3个月对辉瑞股票调仓情况 增减持各5家","url":"https://stock-news.laohu8.com/highlight/detail?id=2553285592","media":"银柿财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553285592?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 09:37","pubTimestamp":1753148273,"startTime":"0","endTime":"0","summary":"据纳斯达克网站消息，有海外机构在25份13F文件分析中发现，辉瑞公司被11家机构持有。在2025年3月31日至6月30日期间，上述机构中5家增持、5家减持、1家持平；在所有1488家持有PFE的机构中，总持股量从90,052,679股降至88,594,320股，净减少1,458,359股，降幅约1.62%。截至2025年6月30日，持有PFE最多的三家机构为： Robeco Institutional Asset Management B.V. 、 Assenagon Asset Management S.A. 、 Swedbank AB 。不过，13F文件仅要求机构向美国证券交易委员会披露多头头寸，而无需披露空头头寸。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722093759a45ae55b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722093759a45ae55b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","LU0868494617.USD","LU1883839398.USD","IE00BBT3K403.USD","LU0321505439.SGD","SG9999011175.SGD","SG9999002224.SGD","LU0234572021.USD","SG9999001176.SGD","BK4588","LU1066051498.USD","LU1894683348.USD","SG9999003800.SGD","SG9999013999.USD","LU0306806265.USD","IE00BLSP4239.USD","BK4585","LU0306807586.USD","SG9999002232.USD","SGXZ57979304.SGD","IE00B19Z3581.USD","LU0122379950.USD","LU0985481810.HKD","LU1066053197.SGD","LU0170899867.USD","LU0225284248.USD","BK4599","BK4550","LU0058720904.USD","BK4581","BK4592","LU1057294990.SGD","IE00BLSP4452.SGD","LU0289739699.SGD","LU0225771236.USD","LU0321505868.SGD","BK4533","LU1023059063.AUD","IE0002270589.USD","IE000M9KFDE8.USD","SG9999001176.USD","BK4007","IE00B19Z3B42.SGD","PFE","LU0456855351.SGD","BK4534","LU1894683264.USD"],"gpt_icon":0},{"id":"2553964400","title":"安进7月21日成交额为5.98亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553964400","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553964400?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 09:16","pubTimestamp":1753146989,"startTime":"0","endTime":"0","summary":"美东时间2025年7月21日，安进成交额为5.98亿美元，成交额较昨日增加2.60%，当日成交量为202.52万股。安进于2025年7月21日涨0.38%，报295.87美元，该股过去5个交易日跌0.39%，年初至今涨15.45%，过去60日涨7.41%。安进于 2006 年推出了首款癌症治疗药物 Vectibix，并销售骨强化药物 Prolia/Xgeva和 Evenity。同时，安进还拥有不断增长的生物仿制药产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722091638a45adb5c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722091638a45adb5c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4534","SG9999001440.SGD","LU0058720904.USD","IE0002141913.USD","BK4588","IE0009355771.USD","IE00B2B36J28.USD","LU2112291526.USD","LU2089984988.USD","IE00BJT1NW94.SGD","BK4581","LU1023059063.AUD","BK4599","IE00B4R5TH58.HKD","LU1571399168.USD","LU0320765992.SGD","BK4139","LU1061106388.HKD","LU2242652126.USD","LU2242646821.SGD","LU2468319806.SGD","LU0289739699.SGD","BK4533","BK4566","LU1057294990.SGD","IE00BJJMRZ35.SGD","LU1983299246.USD","LU0122379950.USD","LU0109394709.USD","LU0889565916.HKD","LU0868494617.USD","AMGN","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2553540965","title":"硕迪生物盘中异动 临近收盘急速跳水5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553540965","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553540965?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 03:36","pubTimestamp":1753126577,"startTime":"0","endTime":"0","summary":"北京时间2025年07月22日03时36分，硕迪生物股票出现异动，股价快速跳水5.09%。截至发稿，该股报18.27美元/股，成交量82.174万股，换手率1.43%，振幅6.65%。机构评级方面，在所有12家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体涨幅为0.05%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072203361797af3f9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072203361797af3f9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","GPCR","BK4007"],"gpt_icon":0},{"id":"2553315782","title":"太平洋医药日报：诺和诺德司美格鲁肽在华获批新适应症 用于治疗慢性肾脏病","url":"https://stock-news.laohu8.com/highlight/detail?id=2553315782","media":"太平洋证券股份...","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553315782?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 00:00","pubTimestamp":1753113600,"startTime":"0","endTime":"0","summary":"该药是一款GLP-1 受体激动剂，目前该产品已经获批用于降低伴有慢性肾脏病的2 型糖尿病成人患者eGFR 持续下降、终末期肾病和心血管死亡的风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722173833954cb504&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722173833954cb504&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","BK4588","LU0154236417.USD","IE00BKVL7J92.USD","LU1093756325.SGD","LU1093756168.USD","BK4599","BK4532","BK4007","BK4585","NVO"],"gpt_icon":1},{"id":"2553047048","title":"美国OTC市场Novo Nordisk A/S盘中异动 快速下挫3.06%报62.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553047048","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553047048?lang=zh_cn&edition=fundamental","pubTime":"2025-07-21 22:03","pubTimestamp":1753106620,"startTime":"0","endTime":"0","summary":"北京时间2025年07月21日22时03分，美国OTC市场Novo Nordisk A/S股票出现波动，股价大幅下跌3.06%。截至发稿，该股报62.60美元/股，成交量113股，换手率0.00%，振幅3.67%。美国OTC市场Novo Nordisk A/S股票所在的制药行业中，整体涨幅为0.08%。美国OTC市场Novo Nordisk A/S公司简介：诺和诺德拥有全球约三分之一的品牌糖尿病治疗市场，是全球领先的糖尿病护理产品供应商。诺和诺德还有一个生物制药部门，专门从事血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721220340a6b84d2f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721220340a6b84d2f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","IE00BKVL7J92.USD","LU0154236417.USD","BK4588","BK4007","BK4599","IE00BZ1G4Q59.USD","LU1093756325.SGD","NONOF","NVO","BK4585","LU1093756168.USD"],"gpt_icon":1},{"id":"2553424232","title":"方舟健客与诺和诺德签署合作备忘录，共筑健康管理新生态","url":"https://stock-news.laohu8.com/highlight/detail?id=2553424232","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553424232?lang=zh_cn&edition=fundamental","pubTime":"2025-07-21 14:53","pubTimestamp":1753080800,"startTime":"0","endTime":"0","summary":"7月18日，在第三届中国国际供应链促进博览会上，AI+互联网医疗头部企业方舟健客依托其AI应用服务场景、便捷药事服务等资源，与全球领先的生物制药公司诺和诺德正式签署合作备忘录，携手诺和诺德围绕糖尿病和肥胖症等严重慢性疾病的管理展开项目合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721161810a6b76f86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721161810a6b76f86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","BK4532","LU0154236417.USD","LU1093756168.USD","NVO","BK4599","LU1093756325.SGD","06086","IE00BKVL7J92.USD","BK4007","BK4588","BK4585"],"gpt_icon":1},{"id":"2553440198","title":"诺和泰新增适应症；康华生物控股股东变更｜健讯Daily","url":"https://stock-news.laohu8.com/highlight/detail?id=2553440198","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553440198?lang=zh_cn&edition=fundamental","pubTime":"2025-07-21 10:08","pubTimestamp":1753063718,"startTime":"0","endTime":"0","summary":"此次司美格鲁肽新增慢性肾脏病适应症，有望提高其市场份额，并在这场竞速赛中不断巩固其市场地位。实施后，万可欣生物拥有公司表决权的比例为29.99%，公司控股股东将由王振滔变更为万可欣生物，因万可欣生物无实控人，公司实控人将由王振滔变更为无实控人。本次要约收购完成后，济川药业的股权分布仍符合上市条件，上市地位不受影响。文章来源：21世纪经济报道诺和泰新增适应症；康华生物控股股东变更｜21健讯Daily","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721104535a6b6a666&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721104535a6b6a666&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2065170008.USD","LU2272731782.SGD","LU1923622291.USD","LU2473716301.USD","LU0354030438.USD","LU2106854487.HKD","LU2272731865.HKD","LU2322448957.HKD","NVO","LU2023250843.SGD","LU2023250504.SGD","BK4588","LU2125909916.SGD","BK4532","LU2272731600.USD","LU2506951958.HKD","LU2506952170.USD","BK4599","IE00B775SV38.USD","LU1093756325.SGD","LU2506951875.HKD","IE00BZ1G4Q59.USD","LU2506952097.USD","LU1992135472.HKD","BK4007","LU1917777945.USD","LU2065169927.USD","LU1974910355.USD","LU2065171402.SGD","LU2322448791.USD","LU0154236417.USD","IE00BKVL7J92.USD","LU0823417653.USD","LU2065171311.SGD","BK4020","IE00B3S45H60.SGD","LU0354030511.USD","LU0823417737.USD","LU0950375773.USD","MSI","IE0034235188.USD","LU1093756168.USD","LU1992135399.USD","LU2125909759.SGD","BK4585","LU2247934214.USD"],"gpt_icon":1},{"id":"2552416874","title":"RootData：ALT 将于一周后解锁价值约 867 万美元的代币","url":"https://stock-news.laohu8.com/highlight/detail?id=2552416874","media":"BitPush","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552416874?lang=zh_cn&edition=fundamental","pubTime":"2025-07-19 11:06","pubTimestamp":1752894365,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bitpush.news//articles/7555778","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bit_push_live","symbols":["BK4139","LU1878469433.USD","BK4599","ALT"],"gpt_icon":0},{"id":"2552413745","title":"安进7月18日成交额为5.83亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552413745","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552413745?lang=zh_cn&edition=fundamental","pubTime":"2025-07-19 09:16","pubTimestamp":1752887783,"startTime":"0","endTime":"0","summary":"美东时间2025年7月18日，安进成交额为5.83亿美元，成交额较昨日增加13.49%，当日成交量为196.77万股。安进于2025年7月18日跌1.17%，报294.76美元，该股过去5个交易日跌0.17%，年初至今涨15.02%，过去60日涨6.82%。安进于 2006 年推出了首款癌症治疗药物 Vectibix，并销售骨强化药物 Prolia/Xgeva和 Evenity。同时，安进还拥有不断增长的生物仿制药产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250719091637a6b320b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250719091637a6b320b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0868494617.USD","LU1061106388.HKD","LU2468319806.SGD","AMGN","LU0058720904.USD","SG9999001440.SGD","LU1571399168.USD","LU2089984988.USD","LU0289739699.SGD","BK4566","BK4139","IE00BJT1NW94.SGD","BK4533","LU2112291526.USD","IE0009355771.USD","LU0889565916.HKD","BK4585","LU2242646821.SGD","LU0122379950.USD","IE00B4R5TH58.HKD","BK4588","BK4534","BK4581","LU1983299246.USD","LU0109394709.USD","LU1057294990.SGD","IE0002141913.USD","LU2242652126.USD","IE00B2B36J28.USD","LU0320765992.SGD","IE00BFTCPJ56.SGD","LU1023059063.AUD","BK4599","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2552491472","title":"美国OTC市场Novo Nordisk A/S盘中异动 快速下跌3.12%报63.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552491472","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552491472?lang=zh_cn&edition=fundamental","pubTime":"2025-07-19 00:40","pubTimestamp":1752856859,"startTime":"0","endTime":"0","summary":"北京时间2025年07月19日00时40分，美国OTC市场Novo Nordisk A/S股票出现波动，股价大幅下挫3.12%。截至发稿，该股报63.40美元/股，成交量82.6984万股，换手率0.02%，振幅4.18%。美国OTC市场Novo Nordisk A/S股票所在的制药行业中，整体涨幅为0.49%。美国OTC市场Novo Nordisk A/S公司简介：诺和诺德拥有全球约三分之一的品牌糖尿病治疗市场，是全球领先的糖尿病护理产品供应商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250719004059a6b29cc0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250719004059a6b29cc0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","IE00BKVL7J92.USD","LU1093756325.SGD","BK4532","LU0154236417.USD","IE00BZ1G4Q59.USD","BK4585","NVO","NONOF","BK4007","BK4588","LU1093756168.USD"],"gpt_icon":1},{"id":"2552495660","title":"安进涨0.54% 股价突破300美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2552495660","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552495660?lang=zh_cn&edition=fundamental","pubTime":"2025-07-18 21:32","pubTimestamp":1752845525,"startTime":"0","endTime":"0","summary":"北京时间2025年07月18日21时32分，安进股票出现波动，股价急速拉升0.54%。截至发稿，该股报299.85美元/股，成交量24.6716万股，换手率0.05%，振幅0.60%。最近的财报数据显示，该股实现营业收入80.93亿美元，净利润17.30亿美元，每股收益3.22美元，毛利51.25亿美元，市盈率27.33倍。安进股票所在的制药行业中，整体涨幅为0.15%。安进于 2006 年推出了首款癌症治疗药物 Vectibix，并销售骨强化药物 Prolia/Xgeva和 Evenity。同时，安进还拥有不断增长的生物仿制药产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718213205a6b254b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718213205a6b254b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMGN","IE0009355771.USD","LU1571399168.USD","BK4533","BK4585","LU2089984988.USD","LU0868494617.USD","LU1057294990.SGD","LU0109394709.USD","BK4581","BK4588","LU0289739699.SGD","BK4534","LU0058720904.USD","IE0002141913.USD","LU2112291526.USD","BK4139","SG9999001440.SGD","IE00BFTCPJ56.SGD","LU0889565916.HKD","LU0320765992.SGD","BK4566","LU2242646821.SGD","LU1061106388.HKD","LU1983299246.USD","IE00B2B36J28.USD","LU1023059063.AUD","LU2242652126.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","BK4599","IE00BJJMRZ35.SGD","LU2468319806.SGD","LU0122379950.USD"],"gpt_icon":0},{"id":"2552949844","title":"【官宣！全球生物制药巨头诺和诺德牵手互联网慢病管理巨头方舟健客(06086.HK) 以AI重构控糖减重管理价值链 共筑全","url":"https://stock-news.laohu8.com/highlight/detail?id=2552949844","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552949844?lang=zh_cn&edition=fundamental","pubTime":"2025-07-18 21:19","pubTimestamp":1752844754,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06086","BK1247","BK4007","160636","IE00BKVL7J92.USD","LU1093756168.USD","LU1093756325.SGD","NVO","IE00BZ1G4Q59.USD","BK4585","159792","LU0154236417.USD","BK4532","BK4588","BK4599"],"gpt_icon":0},{"id":"2552672704","title":"打造全周期智控慢病数智化标杆！方舟健客(06086)与诺和诺德签署合作备忘录，共筑健康管理新生态","url":"https://stock-news.laohu8.com/highlight/detail?id=2552672704","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552672704?lang=zh_cn&edition=fundamental","pubTime":"2025-07-18 20:11","pubTimestamp":1752840664,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月18日，在第三届中国国际供应链促进博览会上，AI+互联网医疗头部企业方舟健客依托其AI应用服务场景、便捷药事服务等资源，与全球领先的生物制药公司诺和诺德正式签署合作备忘录，携手诺和诺德围绕糖尿病和肥胖症等严重慢性疾病的管理展开项目合作。展望未来，双方有望持续探索医疗行业在数智化升级过程中的更多创新合作，进一步造福广大严重慢性疾病患者，助力“健康中国2030”战略目标的加速实现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1319630.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1093756325.SGD","06086","LU1093756168.USD","BK1247","IE00BKVL7J92.USD","LU0154236417.USD","BK4007","IE00BZ1G4Q59.USD","BK4588","BK4585","NVO","BK4532","BK4599"],"gpt_icon":1},{"id":"2552311461","title":"诺和诺德寸步不让","url":"https://stock-news.laohu8.com/highlight/detail?id=2552311461","media":"生物制品圈","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552311461?lang=zh_cn&edition=fundamental","pubTime":"2025-07-18 17:34","pubTimestamp":1752831255,"startTime":"0","endTime":"0","summary":"诺和诺德多维进击，寸步不让，持续加码代谢领域。7月8日，诺和诺德向欧洲药品管理局提交的7.2mg司美格鲁肽上市申请获得受理。诺和诺德凭借其前瞻性布局，在GLP-1/Amylin双靶点减重疗法领域取得全球领先地位。诺和诺德计划于2026年第一季度启动其减重III期临床试验。2020年6月，诺和诺德以21亿美元收购Corvidia Therapeutics，获得长效抗IL-6抗体Ziltivekimab。2022年9月，诺和诺德以潜在总价7亿美元引进Ventus Therapeutics的口服NLRP3抑制剂NNC6022-0001。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718182245a453492b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718182245a453492b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756168.USD","IE00BKVL7J92.USD","LU0154236417.USD","BK4585","NVO","BK4588","BK4007","LU1093756325.SGD","BK4532","BK4599","IE00BZ1G4Q59.USD"],"gpt_icon":1},{"id":"2552462341","title":"小细胞肺癌治疗重大突破！百济神州&安进双抗新药在华申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2552462341","media":"药事纵横","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552462341?lang=zh_cn&edition=fundamental","pubTime":"2025-07-18 17:00","pubTimestamp":1752829200,"startTime":"0","endTime":"0","summary":"7月16日，CDE官网显示，百济神州与安进合作开发的注射用塔拉妥单抗上市申请正式获受理。小细胞肺癌的后线治疗选择极为有限。医学界长期将小细胞肺癌后线治疗视为公认的难治领域，这一困境已持续数十年未取得实质性突破。这种创新机制使塔拉妥单抗成为首个用于实体瘤的BiTE药物，为小细胞肺癌治疗开辟了全新路径。百济神州与安进已达成全球肿瘤战略合作，共同推进塔拉妥单抗在中国的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718191410a6b2101b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718191410a6b2101b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BFTCPJ56.SGD","LU0868494617.USD","LU1057294990.SGD","BK4599","IE0009355771.USD","LU2468319806.SGD","AMGN","BK4534","BK4139","IE00B4R5TH58.HKD","06160","LU0058720904.USD","LU2242646821.SGD","688235","IE0002141913.USD","BK4566","BK4533","LU0109394709.USD","LU0320765992.SGD","LU0289739699.SGD","IE00B2B36J28.USD","LU2242652126.USD","ONC","SG9999001440.SGD","BK4588","LU1571399168.USD","LU2089984988.USD","LU1023059063.AUD","LU2112291526.USD","LU0889565916.HKD","LU1983299246.USD","BK4585","IE00BJJMRZ35.SGD","LU1061106388.HKD","IE00BJT1NW94.SGD","BK4581","LU0122379950.USD"],"gpt_icon":0},{"id":"2552465966","title":"刚刚！诺和诺德“司美格鲁肽注射液”新适应症国内获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2552465966","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552465966?lang=zh_cn&edition=fundamental","pubTime":"2025-07-18 16:13","pubTimestamp":1752826408,"startTime":"0","endTime":"0","summary":"7 月 17 日，NMPA 官网显示，诺和诺德司美格鲁肽注射液的获批一项新适应症。根据公开资料和临床试验进展，Insight 数据库推测，本次获批新适应症可能为：成人 2 型糖尿病合并慢性肾脏疾病。安全性方面，司美格鲁肽组报告的严重不良事件数量少于安慰剂组。随着新适应症的不断拓展，司美格鲁肽的销售额无疑将得到进一步的放量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718164641a6b1b115&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718164641a6b1b115&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","LU1093756168.USD","NVO","BK4588","BK4599","LU0154236417.USD","IE00BKVL7J92.USD","BK4585","LU1093756325.SGD","BK4007","IE00BZ1G4Q59.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":115,"code":"91000000","status":"200"}]}}